Возможности монотерапии моксифлоксацином внебольничной пневмонии, осложненной сепсисом
Возможности монотерапии моксифлоксацином внебольничной пневмонии, осложненной сепсисом
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М., 2006.
2. Dillindger RP, Carlet J, Masur H et al. Surviving Sepsis Campaign guidelines for of severe sepsis and septic shock. Crit Care Medecine 2004; 32: 858–73.
3. Сепсис в начале XXI века. Классификация, клинико-диагностическая концепция и лечение. Патолого-анатомическая диагностика: Практическое руководство. М.: Изд-во НЦССХ им. А.Н.Бакулева РАМН, 2004.
4. Mandell L, Bartlett J, Dowell S et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocomplement adulns. Clin Inf Dis 2003; 37: 1405–33.
5. Niederman M, Mandell L, Anzueto A et al. Guidelines for the management of adults of community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therahy and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54.
6. British Thoracic Society Standards Committee. BTS guidelines for the management of community-acqured pneumonia in adults.
7. Macrolides as biologic response modifiers – immunomodulatory and anti-inflammatory effects. Chest 2004; 125 (Suppl.): 415–785.
8. Martinez R, Horcajada JP, Almela M et al. Addition of a macrolides to a – lactams based empirical antibiotic regimen is associated with lower in hospita mortality for patients with bacteremic pneumococcal pneumonia. Clin Inf Dis 2003; 36: 389–95.
9. Baddour LM, Yu V, Klugman K et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440–7.
10. Fogarty C, Siami G, Kochler R et al. Multicenter, openlabel, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxon sodium and erythromycin and amoxicillin-clavulanate in the treatment of serious community-acqured pneumonia in adults. Clin Inf Dis 2004; 38: 16–23.
11. Lode H, Choudhri S, Haverstock D et al. Effcacy and safety of sequential IV/PO moxifloxacin for treatment of severe community-acquired pneumonia. Critical care 2002; 6 (Suppl.): 88.
12. Glynn P, Coacley R, Killgallen I et al. Ciculating interleukin 6 and interleukin 10 in community-acquired pneumonia. Thorax 1999; 54: 51–5.
2. Dillindger RP, Carlet J, Masur H et al. Surviving Sepsis Campaign guidelines for of severe sepsis and septic shock. Crit Care Medecine 2004; 32: 858–73.
3. Сепсис в начале XXI века. Классификация, клинико-диагностическая концепция и лечение. Патолого-анатомическая диагностика: Практическое руководство. М.: Изд-во НЦССХ им. А.Н.Бакулева РАМН, 2004.
4. Mandell L, Bartlett J, Dowell S et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocomplement adulns. Clin Inf Dis 2003; 37: 1405–33.
5. Niederman M, Mandell L, Anzueto A et al. Guidelines for the management of adults of community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therahy and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54.
6. British Thoracic Society Standards Committee. BTS guidelines for the management of community-acqured pneumonia in adults.
7. Macrolides as biologic response modifiers – immunomodulatory and anti-inflammatory effects. Chest 2004; 125 (Suppl.): 415–785.
8. Martinez R, Horcajada JP, Almela M et al. Addition of a macrolides to a – lactams based empirical antibiotic regimen is associated with lower in hospita mortality for patients with bacteremic pneumococcal pneumonia. Clin Inf Dis 2003; 36: 389–95.
9. Baddour LM, Yu V, Klugman K et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440–7.
10. Fogarty C, Siami G, Kochler R et al. Multicenter, openlabel, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxon sodium and erythromycin and amoxicillin-clavulanate in the treatment of serious community-acqured pneumonia in adults. Clin Inf Dis 2004; 38: 16–23.
11. Lode H, Choudhri S, Haverstock D et al. Effcacy and safety of sequential IV/PO moxifloxacin for treatment of severe community-acquired pneumonia. Critical care 2002; 6 (Suppl.): 88.
12. Glynn P, Coacley R, Killgallen I et al. Ciculating interleukin 6 and interleukin 10 in community-acquired pneumonia. Thorax 1999; 54: 51–5.
Авторы
И.Ю.Носков, В.А.Руднов
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.